Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6006685 | 0.79 | — | — | |
| SCHEMBL8176900 | 0.77 | NAAA (0.35) | P2RX7ALDH1A1 | |
| SCHEMBL6008601 | 0.76 | NAAA (0.37) | KCNH3ALDH1A1 | |
| SCHEMBL772291 | 0.74 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6004967 | 0.72 | FDPS (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6007517 | 0.72 | — | — | |
| SCHEMBL1996668 | 0.71 | — | — | |
| SCHEMBL1997311 | 0.71 | — | — | |
| SCHEMBL16606307 | 0.71 | ALDH1A1 (0.39) | KCNH3P2RX7ALDH1A1SMN1; SMN2 | |
| SCHEMBL4335988 | 0.70 | MTNR1A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237410-B1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2020-12-16 | — | — | EP | claimed |
| EP-3237410-B1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2020-12-16 | — | — | EP | disclosed |
| US-10273231-B2 | Azoline compounds substituted by a condensed ring system | BASF SE (DE) | 2019-04-30 | — | — | US | disclosed |
| US-20190040050-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2019-02-07 | — | — | US | disclosed |
| US-10093662-B2 | Azoline compounds substituted by a condensed ring system | BASF SE (DE) | 2018-10-09 | — | — | US | disclosed |
| US-20180002323-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2018-01-04 | — | — | US | disclosed |
| EP-3237410-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2999338-B1 | KNOWN AND NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016102482-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | BASF SE (DE) | 2016-06-30 | — | — | WO | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-0807105-B1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| US-5994368-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040050-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | CUL5, CUL1, CUL3 | KCNH3 794/4885P2RX7 1680/4885ALDH1A1 1791/4885 |
| US-20180002323-A1 | AZOLINE COMPOUNDS SUBSTITUTED BY A CONDENSED RING SYSTEM | CUL1, CRY1, CUL5 | KCNH3 818/4885P2RX7 3544/4885ALDH1A1 1313/4885 |
| US-10093662-B2 | Azoline compounds substituted by a condensed ring system | CUL1, CRY1, CUL5 | KCNH3 818/4885P2RX7 3544/4885ALDH1A1 1313/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | KCNH3 1284/4885P2RX7 2051/4885ALDH1A1 228/4885 |
| US-10273231-B2 | Azoline compounds substituted by a condensed ring system | CUL5, CUL1, CUL3 | KCNH3 794/4885P2RX7 1680/4885ALDH1A1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.